Skip to main content
PEPTARA LABS
Get Started

Tirzepatide Side Effects

Tirzepatide Side Effects: What the Trials Actually Report

Published by · Updated · How we research and check our pages

The short answer

The most commonly reported tirzepatide side effects in the SURMOUNT-1 obesity trial were gastrointestinal, led by nausea, diarrhea, constipation, and vomiting (Jastreboff et al., NEJM 2022). They were dose-related, mostly mild to moderate, and clustered in the early weeks of the trial. Discontinuation because of adverse events was low, about 4 to 7 percent across the studied doses versus about 3 percent on placebo. This page reports what published trials found. It is not medical advice.

This page is general educational information, research-use framing only, not medical advice. Research-grade tirzepatide is supplied for laboratory research only, not for human use.

What are the most common tirzepatide side effects?

The most common tirzepatide side effects reported in SURMOUNT-1 were gastrointestinal, led by nausea, diarrhea, constipation, and vomiting (Jastreboff et al., NEJM 2022; doi:10.1056/NEJMoa2206038).

SURMOUNT-1 was a 72-week phase 3 trial in 2,539 adults with obesity, or overweight with a weight-related condition, who did not have type 2 diabetes (Jastreboff et al., NEJM 2022). Across the studied doses, most adverse events were mild to moderate in severity, and the gastrointestinal symptoms below were the events that separated tirzepatide from placebo most clearly.

The ranges below reflect what SURMOUNT-1 reported across its three tirzepatide dose groups (Jastreboff et al., NEJM 2022).

Adverse eventReported on tirzepatide (across studied doses)PlaceboSource
Nauseaabout 25 to 33 percentabout 10 percentJastreboff et al., NEJM 2022
Diarrheaabout 19 to 23 percentabout 7 percentJastreboff et al., NEJM 2022
Constipationabout 12 to 17 percentabout 6 percentJastreboff et al., NEJM 2022
Vomitingabout 8 to 12 percentabout 2 percentJastreboff et al., NEJM 2022

Values are approximate and rounded from the trial's reported rates by dose group, lowest to highest (nausea 24.6, 33.3, and 31.0 percent; diarrhea 18.7, 21.2, and 23.0 percent; constipation 16.8, 17.1, and 11.7 percent; vomiting 8.3, 10.7, and 12.2 percent).

Are tirzepatide side effects dose-related?

Yes: SURMOUNT-1 reported that gastrointestinal side effects generally became more frequent at higher doses (Jastreboff et al., NEJM 2022).

Rates were reported for each of the three dose groups, which is why they appear as ranges (Jastreboff et al., NEJM 2022). Nausea and vomiting, for example, tended to sit toward the higher end in the higher dose groups.

When do tirzepatide side effects tend to happen?

Trial data reported that gastrointestinal side effects were concentrated in the early part of the trial and less prominent later (Jastreboff et al., NEJM 2022).

In SURMOUNT-1, nausea, vomiting, and related symptoms were concentrated in the early weeks rather than spread evenly across the full 72 weeks (Jastreboff et al., NEJM 2022). The SURPASS-2 diabetes trial described the same timing for both tirzepatide and semaglutide, with gastrointestinal events occurring mainly early in the trial (Frias et al., NEJM 2021).

How many trial participants stopped tirzepatide because of side effects?

Discontinuation due to adverse events was low in SURMOUNT-1, at about 4 to 7 percent across the studied doses compared with about 3 percent on placebo (Jastreboff et al., NEJM 2022).

By dose group, treatment discontinuation for adverse events was reported at 4.3, 7.1, and 6.2 percent, lowest to highest, versus 2.6 percent on placebo (Jastreboff et al., NEJM 2022). In other words, most participants who reported side effects stayed in the trial. Serious adverse events were reported in a low share of participants and were broadly similar between the tirzepatide and placebo groups. This is trial-level data and does not predict any individual's experience.

How does tirzepatide compare with semaglutide for side effects?

In the head-to-head SURPASS-2 trial, tirzepatide and semaglutide both produced a gastrointestinal-predominant side-effect profile, with nausea, diarrhea, and vomiting among the most common events for each (Frias et al., NEJM 2021; doi:10.1056/NEJMoa2107519).

SURPASS-2 studied adults with type 2 diabetes, so its population differs from SURMOUNT-1, but the pattern was consistent. The trial reported nausea in about 17 to 22 percent of the tirzepatide groups versus about 18 percent for semaglutide, diarrhea in about 13 to 16 percent versus about 12 percent, and vomiting in about 6 to 10 percent versus about 8 percent (Frias et al., NEJM 2021). Both were described as mostly mild to moderate. For a fuller side-by-side, see the comparison page linked below.

What happened when tirzepatide was withdrawn?

Withdrawal is not a side effect, but the SURMOUNT-4 trial reported that participants switched from tirzepatide to placebo tended to regain a substantial share of the weight they had lost (Aronne et al., JAMA 2024).

In SURMOUNT-4, after a 36-week open-label lead-in on tirzepatide, participants were randomized either to continue or to switch to placebo. The group that stopped regained weight over the following months, while the group that continued kept and added to their earlier reduction (Aronne et al., JAMA 2024). This matters for reading the results: the trial data describe an ongoing therapy, and outcomes after withdrawal differed from outcomes during treatment.

How far do trial averages generalize?

Mainly to similar populations: SURMOUNT-1 reports averages across a defined trial population, adults with obesity or overweight who did not have type 2 diabetes, and results in other groups can differ (Jastreboff et al., NEJM 2022).

Peptara Labs supplies materials for laboratory research only, not for human use. The figures on this page are here to give the primary evidence clearer context.

Questions about how these trial groups were chosen?

The section above explains which group of people the main trial enrolled and how far its averages apply. Peptara Labs research compounds are for laboratory research use only. A real member of our team answers questions on WhatsApp.

Ask on WhatsApp

Tirzepatide Side Effects: FAQ

What is the single most common tirzepatide side effect?

Nausea was the most frequently reported adverse event in SURMOUNT-1, affecting roughly a quarter to a third of participants at the studied doses versus about 10 percent on placebo (Jastreboff et al., NEJM 2022).

Were most tirzepatide side effects serious?

No. The trial reported that most adverse events were mild to moderate gastrointestinal symptoms, and serious events were uncommon and similar to placebo (Jastreboff et al., NEJM 2022).

Did tirzepatide side effects ease later in the trial?

Trial data reported that gastrointestinal symptoms were concentrated in the first 20 weeks of the trial and less frequent afterward (Jastreboff et al., NEJM 2022).

Is tirzepatide harder on the stomach than semaglutide?

In SURPASS-2, both drugs showed a similar gastrointestinal-predominant profile rather than one being clearly gentler across the board (Frias et al., NEJM 2021).

Did weight return after tirzepatide was withdrawn?

SURMOUNT-4 reported weight regain after tirzepatide was withdrawn (Aronne et al., JAMA 2024). This is a discontinuation outcome, not a side effect of the drug itself.

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
  2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647.
  3. Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.

Chat with us